PubRank

Mario P Colombo

Author PubWeight™ 102.42‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006 6.61
2 The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007 4.37
3 IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol 2003 3.69
4 Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003 3.47
5 The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 2008 3.21
6 Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 2005 2.83
7 p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 2006 2.76
8 Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A 2005 2.49
9 OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 2008 2.46
10 Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007 2.41
11 Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 2004 2.38
12 Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002 2.25
13 Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood 2007 2.03
14 Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res 2006 1.97
15 CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 2008 1.95
16 Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. J Exp Med 2010 1.88
17 Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. Cancer Res 2008 1.61
18 IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. J Immunol 2004 1.58
19 Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. Cancer Metastasis Rev 2010 1.52
20 Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood 2012 1.52
21 Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. Blood 2009 1.48
22 Defective stromal remodeling and neutrophil extracellular traps in lymphoid tissues favor the transition from autoimmunity to lymphoma. Cancer Discov 2013 1.47
23 Nucleofection is an efficient nonviral transfection technique for human bone marrow-derived mesenchymal stem cells. Stem Cells 2005 1.47
24 Lipopolysaccharide or whole bacteria block the conversion of inflammatory monocytes into dendritic cells in vivo. J Exp Med 2003 1.39
25 CD40/CD40L interaction regulates CD4+CD25+ T reg homeostasis through dendritic cell-produced IL-2. Eur J Immunol 2005 1.30
26 Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res 2010 1.28
27 Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res 2005 1.28
28 Reconstitution of human telomerase reverse transcriptase expression rescues colorectal carcinoma cells from in vitro senescence: evidence against immortality as a constitutive trait of tumor cells. Cancer Res 2005 1.24
29 Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest 2003 1.17
30 Triggering CD40 on endothelial cells contributes to tumor growth. J Exp Med 2006 1.15
31 Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res 2006 1.14
32 CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. J Clin Invest 2010 1.10
33 Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma. J Exp Med 2003 1.08
34 Role of PLZF in melanoma progression. Oncogene 2004 1.07
35 Accelerated dendritic-cell migration and T-cell priming in SPARC-deficient mice. J Cell Sci 2005 1.04
36 A non-redundant role for OX40 in the competitive fitness of Treg in response to IL-2. Eur J Immunol 2010 1.02
37 Angiopoietin decoy secreted at tumor site impairs tumor growth and metastases by inducing local inflammation and altering neoangiogenesis. Cancer Immunol Immunother 2004 0.98
38 CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J Immunol 2006 0.97
39 The aryl hydrocarbon receptor modulates acute and late mast cell responses. J Immunol 2012 0.95
40 Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res 2011 0.95
41 Chaperon and adjuvant activity of hsp70: different natural killer requirement for cross-priming of chaperoned and bystander antigens. Cancer Res 2005 0.95
42 SPARC oppositely regulates inflammation and fibrosis in bleomycin-induced lung damage. Am J Pathol 2011 0.94
43 Constitutive activation of the ETS-1-miR-222 circuitry in metastatic melanoma. Pigment Cell Melanoma Res 2011 0.92
44 Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis. Cancer Res 2010 0.91
45 Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer. Front Immunol 2013 0.91
46 Enhanced efficacy of tumor cell vaccines transfected with secretable hsp70. Cancer Res 2004 0.91
47 OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response. J Immunol 2003 0.91
48 IL-15 cis presentation is required for optimal NK cell activation in lipopolysaccharide-mediated inflammatory conditions. Cell Rep 2013 0.90
49 The bone marrow stroma in hematological neoplasms--a guilty bystander. Nat Rev Clin Oncol 2011 0.89
50 The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-221&222-c-FOS pathway. Int J Cancer 2013 0.89
51 Exacerbated experimental autoimmune encephalomyelitis in mast-cell-deficient Kit W-sh/W-sh mice. Lab Invest 2011 0.87
52 Matricellular proteins at the crossroad of inflammation and cancer. Cancer Lett 2008 0.86
53 Intratumor OX40 stimulation inhibits IRF1 expression and IL-10 production by Treg cells while enhancing CD40L expression by effector memory T cells. Eur J Immunol 2011 0.86
54 Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor. J Immunol 2004 0.86
55 Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of anti-Salmonella typhimurium immunity. J Exp Med 2008 0.86
56 Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol Immunother 2001 0.84
57 Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma. Blood 2002 0.84
58 HOXB7 expression is regulated by the transcription factors NF-Y, YY1, Sp1 and USF-1. Biochim Biophys Acta 2003 0.82
59 Peripheral regulatory T cells and serum transforming growth factor-β: relationship with clinical response to infliximab in Crohn's disease. Inflamm Bowel Dis 2010 0.82
60 In vivo manipulation of dendritic cell migration and activation to elicit antitumour immunity. Novartis Found Symp 2004 0.82
61 Xg expression in Ewing's sarcoma is of prognostic value and contributes to tumor invasiveness. Cancer Res 2010 0.82
62 IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice. Eur J Immunol 2002 0.82
63 Expression levels of insulin receptor substrate-1 modulate the osteoblastic differentiation of mesenchymal stem cells and osteosarcoma cells. Growth Factors 2014 0.82
64 Mast cells in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. Int J Mol Sci 2012 0.82
65 The matricellular protein SPARC supports follicular dendritic cell networking toward Th17 responses. J Autoimmun 2011 0.81
66 Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. Exp Hematol 2005 0.81
67 Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion. Blood 2012 0.81
68 Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases. Int J Cancer 2013 0.80
69 Modulation of FcεRI-dependent mast cell response by OX40L via Fyn, PI3K, and RhoA. J Allergy Clin Immunol 2012 0.80
70 Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15. Cancer Res 2002 0.80
71 Liver follicular helper T-cells predict the achievement of virological response following interferon-based treatment in HCV-infected patients. Antivir Ther 2012 0.78
72 Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress. PLoS One 2013 0.78
73 The Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward. J Transl Med 2008 0.75
74 Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010. Cancer Immunol Immunother 2011 0.75
75 Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16-18 October 2008. Cancer Immunol Immunother 2009 0.75
76 Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009. Cancer Immunol Immunother 2010 0.75
77 Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19-22, 2011: New perspectives in the immunotherapy of cancer. Cancer Immunol Immunother 2012 0.75